PARP1 and hypertensive disorder: Thirty-two weeks of pharmacological PARP-1 inhibition by L-2286 treatment attenuated hypertension induced structural and functional alterations of carotid arteries by a lowered level of oxidative damage and an interference with stress related inflammatory and cell death propagating signaling events.